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Introduction
Compromised liver function as a consequence of  either acute hepatic 
failure or advanced chronic liver disease leads to insufficient detoxification 
of  neurotoxic substances, which accumulate in the blood and are respon-
sible for a broad range of  neurological manifestations. These include 
hepatic encephalopathy (HE) and acquired hepatocerebral degeneration 
(AHD).1 Clinical manifestations usually involve movement disorders and 
cognitive features. In HE, improvement may be seen with purgative 
ammonia-lowering therapies such as lactulose. However, in AHD liver 
transplant is considered the only effective treatment. We present two cases 
of  advanced liver disease with uncommon movement disorders (freezing 
of  gait and ballismus) that reversed with rifaximin.
Case reports
Case 1
A 42-year-old male was first seen in the Neurology clinic due to involun-
tary movements. His medical history included past alcohol and drug abuse, 
hepatitis C virus (HCV) infection, and hepatic cirrhosis Child-Pugh C with 
portal hypertension and hepatopulmonary syndrome. He had been on 
methadone and olanzapine 2.5 mg id for the last 18 months. There were 
reports of  HE episodes in the previous 8 months with consciousness and 
attention fluctuation, dysarthria, and motor incoordination that subsided 
with lactulose treatment. On neurological examination, he presented gen-
eralized chorea with orolingual, cervical, and asymmetric limb involve-
ment (worse on the left), exacerbated by movements. There was also a 
symmetric dystonia of  both hands. The gait was slightly ataxic (Video 1, 
segment 1). Additional neurological examination showed moderate dysar-
thria and dysphagia. Brain MRI revealed T1-weighted hyperintensities in 
the globus pallidus (GP), subthalamic nuclei, and midbrain (Figure 1). 
T2-weighted sequences showed mild bilateral putaminal hyperintensities, 
particularly on the right side. Ammonia levels were elevated (126 μmol/L, 
normal range 26–47 μmol/L) and manganese levels were normal 
(16.5 ng/mL, normal range 4.7–18.3 ng/mL). A basic metabolic screen 
revealed hypoalbuminemia, thrombocytopenia, and an INR of  1.89 and 
excluded other metabolic alterations. One month later he was seen at the 
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Abstract
Background: Chronic hepatic disease can present with extrapyramidal symptoms. We describe two cases that presented with highly unusual movement disorders: ballism and gait freezing.
Case report: Patient 1 is a 42-year-old man with previous episodes of  hepatic encephalopathy (HE) who presented with upper limb dystonia and generalized chorea that progressed to 
ballism. Patient 2 is a 55-year-old woman who presented with pronounced gait freezing. In both patients, features of  HE and acquired hepatocerebral degeneration coexisted. They improved 
markedly, though transiently, with rifaximin.
Discussion: Ammonia-reducing treatments should be considered in patients presenting with movement disorders due to chronic liver disease.
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emergency department, awake and fully oriented, with rapid, involun-
tary, nonstereotypical, violent ballistic limb movements and choreic 
movements of  the tongue and perioral area (Video 1, segment 2). 
Ammonia levels were 150 μmol/L. He was treated with haloperidol 5 mg 
IM with no response and later with lactulose and rifaximin 800 mg id 
with marked improvement of  the ballistic and choreic movements (Video 
1, segment 3). Ammonia values 3 days after treatment were 61 μmol/L.
Since then, maintaining treatment with rifaximin, he oscillated 
between a fully conscious and oriented state with marked hypotonia and 
dysarthria and episodes of  confusion with severe generalized chorea 
(Video 1, segment 4). Ammonia levels also showed significant variation 
(between 78 and 327 μmol/L), with higher values usually in the context 
of  a concurrent infection or constipation. There were, however, some 
doubts on medication adherence.
Case 2
A 55-year-old woman was referred to our movement disorder clinic 
due to gait imbalance and falls with a fluctuating pattern. She had had 
a liver transplant due to alcoholic cirrhosis and developed graft dysfunc-
tion in the first year after transplant, coinciding with imbalance onset. 
Six years later, she had a self-limited period of  confusion associated with 
hyperammonemia. During the following year, she maintained episodic 
confusion and developed difficulty initiating gait, turning, and walking 
through narrow spaces. In her first neurological observation, she pre-
sented slight mental slowness, hypomimia, a wide-based gait with small 
shuffling steps with evident start and turn hesitation, freezing, and 
impaired postural reflexes (Video 2, segment 1). The remaining neuro-
logical evaluation was normal. Brain MRI revealed bilateral and sym-
metric T1-weighted hyperintensities involving the GP and substantia 
nigra (SN) (Figure 1). T2-FLAIR sequences showed small subcortical 
and deep white matter hyperintensities in both hemispheres alongside 
slight increase in the striatum signal. Ammonia levels were elevated, 
fluctuating between 100 and 200 μmol/L. Metabolic screen showed 
mild stable hyperbilirrubinemia without coagulopathy. At last, she was 
admitted to the emergency unit confused and unable to walk. Hepatic 
ultrasound and liver biopsy showed regenerative nodular hyperplasia 
causing portal hypertension, without cirrhosis or rejection. She was ini-
tiated on rifaximin with impressive improvement in cognition and gait, 
which became practically normal in 1 month (Video 2, segment 2). 
Manganese levels at this point were within the normal range 
(10.2 ng/mL). Ammonia levels also showed significant reduction from 
Figure 1.  Brain MRI. Case 1: Axial T1-weighted images showing hyperinten-
sities in GP(A) and mesencephalon(B); Axial T2-weighted image showing mild 
bilateral hyperintensities in striatum and global CSF space enlargement(C). 
Case 2: Axial T1-weighted images revealing symmetric hyperintensities in the 
GP(D) and substantia nigra(E); Axial T2-FLAIR image showing slight increase in 
the striatum signal(E).
Video 1  (case 1). Neurological examination of  patient 1. Segment 1: 
Patient at age 42 showing slight dysarthria, generalized chorea (worse on the left) 
with oromandibular involvement, bilateral hand dystonia and ataxic gait. 
Segment 2: worsening of  involuntary movements, with bilateral ballistic move-
ments of  limbs. Segment 3: after rifaximin treatment, chorea and ballism disap-
peared. A mild hand dystonia and a slightly ataxic gait is evident. Segment 4: 
clinical worsening with mental slowness, hypomimia, positive upper limb myoc-
lonus with axial and appendicular hypotonia, without chorea. This segment is 
part of  a fluctuating disease course, despite treatment.
Video 2  (case 2). Neurological examination of  patient 2. Segment 1: 
Patient at age 53 presenting abnormal gait with start and turn hesitation. 
Segment 2: gait improvement after rifaximin treatment, with remaining mild hes-
itation when turning. Segment 3: Severe gait disorder with marked freezing and 
magnetism in forward gait, which improves when walking backwards or side to side.
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pretreatment (249 μmol/L) to posttreatment levels (55 μmol/L, 1 month 
later). Neuropsychological evaluation at this point revealed a mild mul-
tidomain cognitive impairment; brain MRI showed reduction of  the 
SN T1-weighted hyperintensity.
Despite initial clinical improvement under rifaximin, during the fol-
lowing months she oscillated between days with a normal gait and oth-
ers in which forward gait was impossible due to freezing. Freezing 
partially improved with backward and side-to-side gait, but was not 
affected by visual or auditory cues (Video 2, segment 3). The patient was 
proposed for liver retransplant.
Discussion
Herein, we report two patients with chronic hepatic disease present-
ing with unusual movement disorders, in which features of  both HE and 
AHD are present (Table 1).
The presence of  portosystemic shunt in cirrhotic or noncirrhotic 
portal hypertension allows neurotoxic substances such as ammonia, glu-
tamine, and manganese to bypass the liver and gain access to the cere-
bral circulation. A proinflammatory state leads to brain blood barrier 
disruption and accumulation of  these substances intraparenchymally.1 
Intracellularly, ammonia is converted into glutamine that produces oxi-
dative stress, metabolic disruption, and astrocyte structural changes. 
Ammonia also interferes in the communication between astrocytes and 
neurons, leading to widespread neurological manifestations.1
Hepatic encephalopathy presents with consciousness fluctuation 
ranging from somnolence to coma, neuropsychiatric symptoms includ-
ing attention deficit, psychomotor slowing, and sleep disturbances. 
Movement disorders associated with HE are less prominent than mental 
status features and include asterixis, tremor, hypokinesia, and rigidity.2 
HE usually has a fluctuating course and can be episodic, recurrent, or 
persistent.1 It is generally considered to be caused by hyperammonemia 
and, hence, potentially reversible. Treatment involves reduction of  
ammonia production through laxatives and nonabsorbable antibiotics 
such as rifaximin.2 On the contrary, AHD is a chronic disorder thought 
to be related primarily to manganese deposition in basal ganglia, where 
it causes presynaptic dopaminergic dysfunction and loss of  postsynaptic 
dopaminergic receptors.3 The manganese theory is supported by MRI 
findings, including T1-high signal intensities in GP and adjacent areas. 
This preferential deposition is linked to a different clinical phenotype, 
mainly with cognitive deterioration and movement disorders, including 
tremor, parkinsonism, dystonia, chorea, and ataxia.2 These symptoms 
are usually irreversible, progressive, and resistant to pharmacological 
treatment.1 The main therapeutic option is hepatic transplantation.1
In our cases, the fluctuating course with attention and consciousness 
impairment, hyperammonemia, and the impressive improvement with 
rifaximin are suggestive of  HE. On the contrary, the combination of  
dystonia, oromandibular dyskinesias, and ballistic movements (case 1) 
and a persistent gait disorder (case 2) with typical T1 hyperintensities in 
both patients support an AHD diagnosis. Patient 1 had previously been 
on olanzapine, which could contribute to the oromandibular dyskine-
sias; it cannot, however, justify the whole clinical presentation, giving its 
fluctuating pattern. This patient also presented a HCV infection, which 
has also been associated with movement disorders.4 Hyperkinetic disor-
ders have been described in patients with HCV while under inferfer-
on-alpha treatment, but these have disappeared with treatment 
interruption.5 Case 1 was not under any HCV treatment and therefore 
we believe the virus had no role in the clinical presentation.
Ballismus and isolated gait abnormalities constitute exceptional man-
ifestations of  chronic hepatic disease. Choreic and ballistic movements 
are usually attributed to decreased output from basal ganglia, caused by 
lesion or dysregulation of  subthalamic afferents.6 The T1-hyperintense 
lesions involving the subthalamic nuclei in the brain MRI of  case 1 
Table 1. Clinical and Imaging Findings Suggestive of  HE or AHD in Each Patient
Patient 1 Patient 2
Suggest hepatic encephalopathy Fluctuating course + +
Transient consciousness and attention impairment + +
Hyperammonemia + +
T2 hyperintensities of  basal ganglia + +
Improvement with rifaximin + +
Suggest AHD Persistent gait alteration + (ataxia) +
Dystonia + −
Orobucolingual dyskinesia + −
Chorea + −
Cerebellar dysarthria and ataxia + −
Hypermanganesemia − NA
T1 hyperintensity of  globus pallidus + +
HE: hepatic encephalopathy; AHD: acquired hepatocerebraldegeneration; NA: non applicable; “+”: present; “−”: absent.
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seem to be the cause of  his movement disorder. We found only two 
previous reports of  two patients with bilateral ballism associated with 
hepatic disease, preceded by episodes of  HE. They responded to treat-
ment with haloperidol and lactulose.7,8 A previous paper reported on 
three patients with hepatic cirrhosis and akinetic-rigid parkinsonian 
syndromes that also improved after rifaximin. This was accompanied by 
a T1 signal reduction in GP.9
Regarding the phenotype of  the second patient, there are several 
reports of  gait abnormalities and postural instability in patients with 
hepatic disease.1,2 Usually, they are noticed as part of  a parkinsonian syn-
drome and are more often related to AHD than HE. We have not found 
cases reporting freezing in the setting of  hepatic disease.10 Our patient 
presented with freezing of  gait without other parkinsonian signs apart 
from hypomimia, evoking a frontal gait. The frontal lobe has a crucial 
role in gait initiation, resulting in freezing and magnetism when dam-
aged. Furthermore, disruptions in the networks connecting the cortical 
areas (frontal and parietal), basal ganglia, and the mesencephalic loco-
motor region involved in gait control are considered the main pathogenic 
mechanisms of  freezing and parkinsonian motor features.1,11 This patient 
presented GP damage/T1 hyperintensities and although these are usu-
ally associated with AHD, the improvement with rifaximin suggests that 
ammonia (and, hence, HE) has an essential role. In fact, HE can also 
display GP T1 hyperintensities as well as white matter/periventricular 
T2 hyperintensities, as our patient did.1,2 The presence of  abnormalities 
in both T1W1 and T2-FLAIR sequences also argues in favor of  the 
coexistence of  ammonia and manganese as pathogenic elements (HE 
and ADH) in the same patient. The link between freezing and hyperam-
monemia has also been described in epileptic patients under valproate 
treatment.12 It is conceivable that ammonia is toxic to basal ganglia and 
its gait networks, particularly in susceptible individuals as ours.
Lastly, it is interesting to notice that our patient’s freezing improved 
with backward or side-to-side gait. Freezing associated with parkinson-
ism is usually exacerbated in nonforward gait. Isolated backward freez-
ing has even been described in patients with neurodegeneration with 
iron brain accumulation.13 A mechanism of  external cueing (such as 
touching the wall) in a parkinsonian gait may be responsible for this 
phenomenon. Alternatively, we hypothesize that backward or side-to-
side gait improvement could be a form of  geste antagoniste in a dystonic 
gait, despite the fact that no leg dystonia is evident. A “crab-like” gait 
that improves in side-to-side walking has been described in dystonia.14
A clear distinction between HE and AHD is probably artificial, as 
both processes may happen simultaneously and share pathogenic path-
ways. Other cases with overlapping features between HE and AHD 
have been reported.8 In a small case series of  AHD, previous episodes of  
HE could be identified in up to 60% of  patients.10 Whether HE consti-
tutes a risk factor for AHD remains to be clarified.
In conclusion, ballism and freezing of  gait should be included in 
the neurological manifestations of  portal hypertension, with or with-
out cirrhosis. Treatments that reduce ammonia production, such 
as rifaximin, must be considered even in patients with atypical 
 manifestations. However, these cases illustrate that improvement may 
be transient and that the disease will still progress, favoring the use of  
rifaximin as a bridge to hepatic transplantation in patients with  persistent 
movement disorders.
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